ATE501169T1 - Lactoferrin-peptide, geeignet als in die zelle eindringende peptide - Google Patents

Lactoferrin-peptide, geeignet als in die zelle eindringende peptide

Info

Publication number
ATE501169T1
ATE501169T1 AT06806526T AT06806526T ATE501169T1 AT E501169 T1 ATE501169 T1 AT E501169T1 AT 06806526 T AT06806526 T AT 06806526T AT 06806526 T AT06806526 T AT 06806526T AT E501169 T1 ATE501169 T1 AT E501169T1
Authority
AT
Austria
Prior art keywords
peptide
peptides
cell
penetrating
lactoferrin
Prior art date
Application number
AT06806526T
Other languages
English (en)
Inventor
Roland Brock
Rainer Fischer
Mariola Fotin-Mleczek
Hansjoerg Hufnagel
Norbert Windhab
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Application granted granted Critical
Publication of ATE501169T1 publication Critical patent/ATE501169T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06806526T 2005-12-30 2006-10-25 Lactoferrin-peptide, geeignet als in die zelle eindringende peptide ATE501169T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05028755 2005-12-30
PCT/EP2006/010271 WO2007076904A1 (en) 2005-12-30 2006-10-25 Peptides useful as cell-penetrating peptides

Publications (1)

Publication Number Publication Date
ATE501169T1 true ATE501169T1 (de) 2011-03-15

Family

ID=37491778

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06806526T ATE501169T1 (de) 2005-12-30 2006-10-25 Lactoferrin-peptide, geeignet als in die zelle eindringende peptide

Country Status (16)

Country Link
US (3) US20100061932A1 (de)
EP (1) EP1966240B3 (de)
JP (1) JP5264502B2 (de)
KR (1) KR101317100B1 (de)
CN (1) CN101395180B (de)
AT (1) ATE501169T1 (de)
AU (1) AU2006332193B2 (de)
BR (1) BRPI0620806B8 (de)
CA (1) CA2646833C (de)
DE (1) DE602006020617D1 (de)
ES (1) ES2361621T7 (de)
IL (1) IL192131A (de)
MX (1) MX2008008548A (de)
PL (1) PL1966240T6 (de)
SI (1) SI1966240T1 (de)
WO (1) WO2007076904A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005051366A1 (de) 2005-10-25 2007-04-26 Degussa Gmbh Drug Delivery Systeme
EP2050461A1 (de) * 2007-10-19 2009-04-22 PharmaSurgics in Sweden AB Peptide basierend auf der menschlichen Lactoferrinsequenz und ihre Verwendung
EP2090584A1 (de) * 2008-02-13 2009-08-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Identifikation eines neuartigen Zystein-reichen Peptids zur Zellenpenetration
PL2253326T3 (pl) * 2008-02-28 2018-09-28 Toray Industries, Inc. Kompozycja farmaceutyczna do podawania przeznosowego
CN102869384B (zh) 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
WO2011074578A1 (ja) * 2009-12-14 2011-06-23 国立大学法人北海道大学 脂質膜構造体に細胞透過能を付与および／または脂質膜構造体の細胞透過能を増強するペプチド、ならびにそれらペプチドと結合した脂質を構成脂質として含む、細胞透過能を有するまたは細胞透過能が増強された脂質膜構造体
WO2011084061A1 (en) 2010-01-08 2011-07-14 Universitair Medisch Centrum St. Radboud Cpp (cell penetrating peptide) and its uses
FR2955773B1 (fr) * 2010-02-01 2017-05-26 Commissariat A L'energie Atomique Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
SI2643344T1 (sl) * 2010-11-26 2017-07-31 Evonik Roehm Gmbh Peptid pridobljen iz humanega laktoferina za uporabo kot sredstvo za maskiranje antigena
CN102174078A (zh) * 2011-01-10 2011-09-07 中国药科大学 肿瘤细胞选择性穿膜肽的应用
CN102091036A (zh) * 2011-01-10 2011-06-15 中国药科大学 一种含有抗肿瘤药物的复合脂质体及其制备方法和用途
CN102153629B (zh) * 2011-01-20 2013-07-24 华中科技大学 一种短肽及其应用
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
CA2837588A1 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
CN102988295B (zh) * 2011-09-09 2015-07-29 复旦大学 一种穿膜肽修饰的纳米粒及其制备方法
CN102993296A (zh) * 2011-09-14 2013-03-27 广州格拉姆生物科技有限公司 牛乳铁蛋白肽及其制备方法
WO2013052058A1 (en) * 2011-10-07 2013-04-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
US8669226B2 (en) 2011-10-07 2014-03-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
DE102011055231A1 (de) * 2011-11-10 2013-05-16 Evonik Industries Ag Verfahren zur Bereitstellung von Regelleistung
DE102011055229A1 (de) 2011-11-10 2013-05-16 Evonik Degussa Gmbh Verfahren zur Bereitstellung von Regelleistung mit einem Energiespeicher unter Ausnutzung von Toleranzen bei der Bestimmung der Frequenzabweichung
CN116549655A (zh) 2011-11-24 2023-08-08 苏州宝时得电动工具有限公司 多肽序列设计及其在多肽介导的siRNA传递中的应用
CN103169982B (zh) * 2011-12-23 2015-05-20 中国科学院上海药物研究所 生物活性肽修饰的纳米银及其制备方法和用途
CN103382217B (zh) * 2012-12-11 2015-05-27 任发政 穿膜肽和药物组合物及其制备方法和应用
JP6063094B2 (ja) * 2013-08-12 2017-01-18 スリーエム イノベイティブ プロパティズ カンパニー 経皮送達を促進するためのペプチド
WO2015075747A1 (en) * 2013-11-19 2015-05-28 Council Of Scientific And Industrial Research Cell-penetrating peptide for biomolecule delivery
EP3079723B1 (de) 2013-12-12 2020-05-27 Life Technologies Corporation Membranpenetrierende peptide zur erhöhung der transfektion und zusammensetzungen und verfahren zur verwendung davon
CN103784406A (zh) * 2014-01-20 2014-05-14 同济大学 一种偶联穿膜肽和mmp酶切位点的纳米颗粒
EP3263604A4 (de) * 2015-02-27 2018-11-21 Josho Gakuen Educational Foundation Polysaccharidderivat mit membrandurchlässiger peptidkette
KR101647804B1 (ko) * 2015-06-24 2016-08-11 한국과학기술연구원 신규 세포투과 펩타이드 및 이의 용도
CN108456254B (zh) * 2017-02-20 2021-06-01 中国科学院上海药物研究所 一种tcs-穿膜肽-肿瘤蛋白酶底物肽融合蛋白、其制备方法和用途
WO2018204392A1 (en) 2017-05-02 2018-11-08 Stanford Burnham Prebys Medical Discovery Institute Tumor associated monocyte/macrophage binding peptide and methods of use thereof
CN108101966B (zh) * 2017-12-26 2020-10-27 暨南大学 基于细胞穿膜肽的氧化还原敏感多肽及其在疫苗载体中的应用
IL278469B2 (en) 2018-05-08 2024-02-01 Evonik Operations Gmbh A nanoparticle containing a bioresorbable polyester, a hydrophilic polymer, and an acylated human lactoferrin-derived peptide
CN111499759B (zh) * 2019-01-31 2022-12-20 上海科技大学 一种具有细胞穿膜性的锌指蛋白-乳铁蛋白融合蛋白质及其制备与应用
CA3127985A1 (en) 2019-02-04 2020-08-13 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
CN110078834B (zh) * 2019-05-05 2021-07-30 华中科技大学 一种类短肽、辅助透膜剂及其应用
CN112426438B (zh) * 2019-11-14 2023-12-05 上海鑫湾生物科技有限公司 用于调控酸性环境免疫应答的组合物、其制备方法和用途
WO2023186757A1 (en) 2022-03-30 2023-10-05 Evonik Operations Gmbh Formulations composed of cationic lipids and poly(lactic-co-glycolic acid) for the delivery of polynucleotides into cells
WO2024079331A1 (en) * 2022-10-13 2024-04-18 Stichting Radboud Universitair Medisch Centrum A complex comprising a cargo and a targeting moiety binding intelectin-1
WO2024119101A1 (en) 2022-12-01 2024-06-06 Yale University Stimuli-responsive traceless engineering platform for intracellular payload delivery

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
EP1493825A3 (de) 1990-06-11 2005-02-09 Gilead Sciences, Inc. Verfahren zur Herstellung von Nukleinsäureliganden
JP2818056B2 (ja) 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
JP3207535B2 (ja) * 1992-08-07 2001-09-10 森永乳業株式会社 抗酸化剤
JP3312946B2 (ja) 1993-03-04 2002-08-12 雪印乳業株式会社 ウイルス感染・増殖抑制剤
AU743469C (en) 1996-08-30 2004-02-12 Rolf Bald Mirror-symmetrical selection and evolution of nucleic acids
US6958239B2 (en) 1996-11-21 2005-10-25 Oligos Etc Inc. Three component chimeric antisense oligonucleotides
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
SE9804614A0 (en) * 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
WO2000004132A1 (en) * 1998-07-15 2000-01-27 Samyang Genex Corporation Mass production method of lactoferrin polypeptide from yeast and useful microorganism thereof
JP3681982B2 (ja) * 1998-07-15 2005-08-10 サムヤン ジェネックス コーポレイション 酵母からラクトフェリンポリペプチドを大量生産する方法及びそれに有用な微生物菌株
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
RU2197987C2 (ru) * 2000-07-07 2003-02-10 Закрытое акционерное общество "АСГЛ-Исследовательские Лаборатории" Носитель чужеродной генетической информации для генной терапии

Also Published As

Publication number Publication date
CA2646833C (en) 2019-07-30
IL192131A (en) 2011-10-31
EP1966240B3 (de) 2011-12-28
BRPI0620806A2 (pt) 2011-11-22
WO2007076904A1 (en) 2007-07-12
CA2646833A1 (en) 2007-07-12
IL192131A0 (en) 2008-12-29
DE602006020617D1 (de) 2011-04-21
KR20080091120A (ko) 2008-10-09
US20100061932A1 (en) 2010-03-11
MX2008008548A (es) 2008-09-10
EP1966240A1 (de) 2008-09-10
EP1966240B1 (de) 2011-03-09
KR101317100B1 (ko) 2013-10-15
BRPI0620806B1 (pt) 2017-12-05
PL1966240T3 (pl) 2011-08-31
CN101395180B (zh) 2016-06-22
US20160151504A1 (en) 2016-06-02
JP5264502B2 (ja) 2013-08-14
PL1966240T6 (pl) 2012-05-31
JP2009521908A (ja) 2009-06-11
SI1966240T1 (sl) 2011-06-30
ES2361621T3 (es) 2011-06-20
CN101395180A (zh) 2009-03-25
US9403884B2 (en) 2016-08-02
US20130108662A1 (en) 2013-05-02
BRPI0620806B8 (pt) 2022-07-05
ES2361621T7 (es) 2012-06-14
AU2006332193A1 (en) 2007-07-12
AU2006332193B2 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
ATE501169T1 (de) Lactoferrin-peptide, geeignet als in die zelle eindringende peptide
Wang et al. Charge and hydrophobicity of casein peptides influence transepithelial transport and bioavailability
ATE485386T1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
BRPI0606934A2 (pt) Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado
NZ598159A (en) Transport molecules using reverse sequence hiv-tat polypeptides
MX357674B (es) Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos.
BRPI0411475A (pt) adições de código genético de aminoácido reativo não natural
PE20100253A1 (es) Mutantes de fgf21
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
DE602006016468D1 (de) Verfahren zur abgabe von fusionspolypeptid in eine zelle
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
ATE408699T1 (de) Verabreichung von nukleinsäuren und proteinen an zellen
WO2003065003A3 (en) Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
BRPI0410562A (pt) molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo
WO2007089334A3 (en) Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein
ATE490266T1 (de) In zellen eindringende peptide als träger für moleküle
ATE529445T1 (de) Biokinetik zur schnellen beseitigung von polypeptiden
Aito-Inoue et al. Improvement in isolation and identification of food-derived peptides in human plasma based on precolumn derivatization of peptides with phenyl isothiocyanate
WO2004067555A3 (en) Protein and peptide delivery to mammalian cells in vitro
PE20020875A1 (es) Peptidos supersegregables en procedimientos para su produccion y para la mejora en paralelo de las formas exportadas de uno o mas de otros peptidos de interes
TW200722521A (en) Novel bioconjugation reactions for acylating polyethylene glycol reagents
ATE532793T1 (de) Verfahren zur herstellung von molekülen mit verminderter immunogenität
KR102305279B1 (ko) 카스파제 억제제의 존재하에 진핵 세포 용해물을 이용한 무세포 단백질 합성방법 및 장치 및 상기 합성방법에서 합성된 단백질의 수율 및/또는 안정성을 향상시키기 위한 카스파제 억제제의 용도
WO2007106603A3 (en) Specific labeling of proteins with zinc finger tags and use of zinc-finger-tagged proteins for analysis
Abou-Diab et al. Eco-circular production of demineralized bioactive peptides from bovine hemoglobin by performing the necessary steps simultaneously using Bipolar Membrane Electrodialysis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1966240

Country of ref document: EP